Morgan Stanley analyst Kall Titchmarsh initiated coverage of MiniMed (MMED) with an Overweight rating and $19 price target reflecting a 31% upside from the current price. The firm expects the company’s pharmacy channel transition to sustain a reimbursement premium over durable medical equipment in the short-to-medium term as pump adoption scales. It sees MiniMed growing from under $100M in revenue in fiscal 2026 to nearly $400M annually by fiscal 2030, driven by Smart MDI penetration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMED: